Advanced Biological Laboratories, Mayo Medical Laboratories Announce Collaboration
LUXEMBOURG--(BUSINESS WIRE)--Advanced Biological Laboratories (ABL), S.A, and Mayo Medical Laboratories have announced a collaboration agreement to develop a deep-sequencing pipeline for novel diagnostic laboratory-developed tests. The novel tests will be validated using clinical samples selected by the Mayo Clinic Division of Clinical Microbiology. The collaboration will also seek to generate a sequence database to which clinical isolates can be compared. Advanced information technology developments will be led by ABL under the expertise of Mayo Clinic staff.
Based in Luxembourg, Advanced Biological Laboratories develops information technology and health solutions for patient management and sequencing data analysis. Mayo Medical Laboratories is the reference laboratory of Mayo Clinic, the world-renowned health care organization located in Rochester, Minnesota.
“Properly validated and characterized laboratory-developed tests offer valuable direction to clinicians and virologists. They guide the selection of optimal treatments and diagnostic monitoring for patients suffering from genetically variable virological diseases of either an acute or chronic nature,” says ABL Chief Executive Officer Chalom Sayada, M.D., Ph.D. “When developed in a timely manner, these tests can be crucial to improved clinical outcomes and decreases in treatment failures, adverse events, and healthcare costs.”
Mayo Clinic also receives access to a range of ABL’s virology products for genotyping data analysis, either from Sanger or Next Generation Sequencing. ABL’s products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module is an FDA registered class I medical device.
Financial terms of the agreements have not been disclosed.
Advanced Biological Laboratories (ABL), S.A., is a medical data technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004, and in 2013, the company acquired the rights to all viral hepatitis B- and C-related assets from EVIVAR MEDICAL. ABL has a comprehensive suite of health care management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and OncoChek™, which are used for data and patient management, monitoring, and personalized reporting applications. In 2012, some of ABL’s products received CE-marking for IVD use. ABL’s products offer clinicians and laboratories optimal and efficient IT solutions for sequencing, clinical genotyping, and drug-resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. Learn more at the company’s website: www.ablsa.com.
About the Mayo Clinic Department of Laboratory Medicine and Pathology and Mayo Medical Laboratories
Mayo Medical Laboratories is the reference laboratory of the Department of Laboratory Medicine and Pathology at Mayo Clinic, a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. Mayo Medical Laboratories is the third-largest provider of esoteric laboratory services in the United States and serves more than 4,000 health care organizations around the world. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 150 new tests each year. Ultimately, these new technologies and new testing are available to the Mayo Clinic practice and other health care institutions through Mayo Medical Laboratories. Revenue from this testing is used to support medical education and research at Mayo Clinic.